BioStem (BSEM) Director Warrington Exercises 5,094 Derivative Units

What Happened
Kenneth Howard Warrington Jr., a director of BioStem Technologies, converted/exercised 5,094 derivative units into common shares on August 27, 2026 (reported on Form 4 filed 2026-08-28). The filing shows an acquisition of 5,094 shares at $0.00 and a matching disposition of 5,094 shares at $0.00 — both reported as transaction code M (exercise or conversion of derivative). No cash value is reported for these transactions.

Key Details

• Transaction date: 2026-08-27; Form 4 filed: 2026-08-28 (timely filing).
• Transactions reported: M = exercise/conversion of derivative — 5,094 shares acquired @ $0.00 and 5,094 shares disposed @ $0.00.
• Reported value: $0.00 (no cash exchanged in the reported transactions).
• Shares owned after transaction: not specified in the excerpt of the filing.
• Relevant footnotes from the filing:
  • F1: Options referenced are fully vested and exercisable.
  • F2: Each restricted stock unit (RSU) represents a contingent right to one share.
  • F3: Some RSUs vest in equal quarterly installments over three years from Sept 15, 2024.
  • F4: Other RSUs vested quarterly over the year following the grant date (Aug 27, 2025).
• Exhibit/remarks: Exhibit 24 — Power of Attorney included.

Context
Transaction code M indicates an exercise or conversion of a derivative (options/RSUs). Because the filing shows both acquisition and immediate disposition of the same number of shares at $0.00, this appears to be an internal conversion/settlement event rather than an open-market buy or sale by the director. Such conversions/vestings are common for option/RSU compensation and do not necessarily signal a buy/sell market opinion.